| 寿胎丸联合地屈孕酮对不明原因复发性流产患者外周血T淋巴细胞亚群的影响 |
|
| DOI： |
| 中文关键词: 复发性流产 T 淋巴细胞亚群 寿胎丸 保胎 |
| 英文关键词: |
| 基金项目:名称:中药复方寿胎丸对复发性流产患者外周血淋巴细胞的影响 编号:2023013068 |
|
| 摘要点击次数: |
| 全文下载次数: |
| 中文摘要: |
| 【】 目的:观察中药寿胎丸联合地屈孕酮片对复发性流产再妊娠患者的临床疗效,并从母胎免疫调控探讨该方的保胎作用机制。方法:将2023 年8月-2025 年1月于河北燕达医院生殖医学科就诊的不明原因RSA患者70例,随机分为研究组及对照组各35例。对照组患者口服地屈孕酮片进行治疗,研究组在对照组用药基础上联合应用中药复方寿胎丸,两组均持续用药至孕12周,观察比较两组用药前后淋巴细胞亚群实验室指标: CD4+、CD8+淋巴细胞的比例以及CD4+/CD8+比值的变化情况及孕12周持续妊娠情况。结果:1.实验室检测指标比较:组内比较:两组用药后RSA再妊娠妇女外周血CD4+淋巴细胞的比例水平及CD4+/CD8+比值均低于治疗前；两组用药后RSA再妊娠妇女外周血CD8+淋巴细胞的比例水平均高于治疗前。组间比较:研究组用药后CD4+淋巴细胞的比例水平及CD4+/CD8+比值明显低于对照组,CD8+淋巴细胞的比例水平明显高于对照组,差异具有统计学意义( P ＜0．05)；2.孕12 周持续妊娠率:研究组明显高于对照组,差异有统计学意义( P ＜0．05)。结论:应用寿胎丸联合地屈孕酮可显著改善复发性流产患者外周血T 淋巴细胞亚群比例,CD4+/ CD8+的比值向CD8+优势转化,诱导妊娠免疫耐受,纠正母体免疫失调状态,提高持续妊娠率,临床疗效满意。 |
| 英文摘要: |
| Objective: To observe the clinical efficacy of Shoutai Pill combined with dydrogesterone tablets in patients with recurrent spontaneous abortion (RSA) during pregnancy and explore the mechanism of its pregnancy protection effect from the perspective of maternal-fetal immune regulation. Methods: A total of 70 patients with unexplained RSA who visited the Reproductive Medicine Department of Hebei Yanda Hospital from August 2023 to January 2025 were randomly divided into a study group and a control group, with 35 cases in each group. The control group was treated with dydrogesterone tablets, while the study group was treated with Shoutai Pill in addition to the medication of the control group. Both groups were treated until the 12th week of pregnancy. The changes in laboratory indicators of lymphocyte subsets, including the proportion of CD4+ and CD8+ lymphocytes and the CD4+/CD8+ ratio, before and after treatment were observed and compared, as well as the rate of continuous pregnancy at the 12th week. Results: 1. Comparison of laboratory test indicators: Intra-group comparison: The proportion of CD4+ lymphocytes and the CD4+/CD8+ ratio in the peripheral blood of RSA patients in both groups after treatment were lower than those before treatment; the proportion of CD8+ lymphocytes was higher than that before treatment. Inter-group comparison: After treatment, the proportion of CD4+ lymphocytes and the CD4+/CD8+ ratio in the study group were significantly lower than those in the control group, and the proportion of CD8+ lymphocytes was significantly higher than that in the control group, with statistically significant differences (P < 0.05). 2. Rate of continuous pregnancy at the 12th week: The rate in the study group was significantly higher than that in the control group, with a statistically significant difference (P < 0.05). Conclusion: The application of Shoutai Pill combined with dydrogesterone can significantly improve the proportion of T lymphocyte subsets in the peripheral blood of RSA patients, shift the CD4+/CD8+ ratio towards a CD8+ advantage, induce pregnancy immune tolerance, correct the immune imbalance of the mother, and increase the rate of continuous pregnancy, with satisfactory clinical efficacy. |
|
View Fulltext
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|